Explore the frontier of life sciences and healthcare innovation. From breakthrough therapeutics and longevity research to the deep tech investments shaping tomorrow's treatments, discover the trends and breakthroughs redefining global health.
Generate:Biomedicines has moved its AI-engineered anti-TSLP antibody GB-0895 into two global Phase 3 trials in severe asthma. 1,600 patients, six-month dosing, $457.4M in cash. The readout will revalue the entire generative-biology cohort.
Superluminal Medicines closed an oversubscribed $60M Series B on September 3 to take a biased MC4R agonist into Phase 1 by the end of 2026. The rare-genetic-obesity slice of the obesity boom runs on orphan-drug economics, and no GLP-1 giant has solved it yet.
The FDA approved Zanvastro (zilganersen), the first disease-modifying treatment for Alexander disease. A 54-patient study showed walking speed held at week 61; Ionis launches it solo with a Priority Review Voucher in hand.
CuspAI raised $450M at a $2.6B valuation to invent materials on demand. Its first proof point is PFAS: 20 AI-designed candidates to strip forever chemicals from drinking water, delivered in six months. The open question for investors: does a designed molecule survive contact with real water?
Tenax's LEVEL trial missed its primary endpoint, yet the biomarker and subgroup data - a 49% NT-proBNP reduction and 26.3-meter walk improvement in high-burden patients - reframe the path to a first PH-HFpEF approval.
A first-in-class hepcidin mimetic just won FDA approval for polycythemia vera. The VERIFY data behind it, the Takeda-Protagonist deal, and what a procedure-replacing platform means for a rare blood disease.
Arintra raised $25M to make agentic AI the engine of hospital revenue assurance. With coders in short supply and 15% of private claims denied upfront, its platform reports a 5.1% lift in compliant revenue.
Biosphere's acquisition of NovoNutrients puts the CO2-to-protein thesis on new footing: the durable asset is the bioreactor, not the organism.